All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Ibrutinib in patients with steroid-refractory cGvHD: Results from a real-world analysis
Bookmark this article
|
A multicenter, real-world observational study assessed the safety and efficacy of ibrutinib, a BTK inhibitor, in 270 patients with SR-cGvHD from 19 centers in the US.1 Results from this analysis were published in Blood Advances by Pidala et al.1 |
| Key learnings |
| Among the 131 evaluable patients, the ORR, CR, and PR rates were 45%, 3%, and 42%, respectively, with a median DOR of 15 months. |
| At a median follow-up of 30.5 months, the 6-month and 12-month FFS rates were 59% and 41%, respectively, and the 6-month and 12-month OS rates were 93% and 87%, respectively. |
| In the multivariable analysis, increased age (HR, 1.01; 95% CI, 1.0–1.02; p = 0.033), higher baseline prednisone dose (HR, 1.92; 95% CI, 1.09–3.38; p = 0.032), and lung involvement (HR, 1.58; 95% CI, 1.1–2.28; p = 0.016) were associated with worse FFS. |
| Results from this study confirm the safety and efficacy of ibrutinib in a real-world setting in patients with SR-GvHD and highlight the factors associated with worse outcomes. |
Abbreviations: BTK, Bruton’s tyrosine kinase; cGvHD, chronic graft-versus-host disease; CI, confidence interval; CR, complete response; DOR, duration of response; FFS, failure-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PR, partial response; SR-cGvHD, steroid-refractory cGvHD.
- Pidala JA, Kim J, Kalos D, et al. Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis. Blood Adv. 2024. Online ahead of print. DOI: 10.1182/bloodadvances.2024014374
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox